EA201991812A1 - Композиции и способы для визуализации и лучевой терапии рака - Google Patents

Композиции и способы для визуализации и лучевой терапии рака

Info

Publication number
EA201991812A1
EA201991812A1 EA201991812A EA201991812A EA201991812A1 EA 201991812 A1 EA201991812 A1 EA 201991812A1 EA 201991812 A EA201991812 A EA 201991812A EA 201991812 A EA201991812 A EA 201991812A EA 201991812 A1 EA201991812 A1 EA 201991812A1
Authority
EA
Eurasian Patent Office
Prior art keywords
radiotherapy
visualization
cancer
compositions
methods
Prior art date
Application number
EA201991812A
Other languages
English (en)
Inventor
Седрик Малисе
Паскалин Лекорш
Джонатан Новак
Марион Давид
Джамаль Темсамани
Мишель Крещатиски
Original Assignee
Вект-Орус
Сантр Насьональ Де Ля Решерш Сьентифик
Юниверситэ Де' Э-Марсей
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вект-Орус, Сантр Насьональ Де Ля Решерш Сьентифик, Юниверситэ Де' Э-Марсей filed Critical Вект-Орус
Publication of EA201991812A1 publication Critical patent/EA201991812A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к конъюгированному соединению, содержащему фармацевтически приемлемый маркер M и пептид или псевдопептид P, имеющий не более 30 аминокислотных остатков и способный связываться с рецептором липопротеинов низкой плотности (LDLR), и к его применению в способе маркировки и/или обнаружения и/или лечения раковых клеток у субъекта путем введения конъюгированного соединения субъекту с помощью анализа присутствия и/или количества маркера.
EA201991812A 2017-01-30 2018-01-30 Композиции и способы для визуализации и лучевой терапии рака EA201991812A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305098 2017-01-30
PCT/EP2018/052234 WO2018138372A1 (en) 2017-01-30 2018-01-30 Compositions and methods for cancer imaging and radiotherapy

Publications (1)

Publication Number Publication Date
EA201991812A1 true EA201991812A1 (ru) 2020-01-23

Family

ID=58043988

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991812A EA201991812A1 (ru) 2017-01-30 2018-01-30 Композиции и способы для визуализации и лучевой терапии рака

Country Status (9)

Country Link
US (2) US11712486B2 (ru)
EP (1) EP3573668A1 (ru)
JP (2) JP2020506921A (ru)
CN (1) CN110536705A (ru)
AU (1) AU2018211539B2 (ru)
BR (1) BR112019015588A2 (ru)
CA (1) CA3049508A1 (ru)
EA (1) EA201991812A1 (ru)
WO (1) WO2018138372A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202102268A (zh) * 2019-04-03 2021-01-16 美商塔維達治療公司 Ｈｓｐ９０靶定性共軛體類及其調製劑
CN110172084A (zh) * 2019-05-24 2019-08-27 哈尔滨医科大学 68Ga标记NODAGA修饰c-Met分子探针及制备与应用
US20230226231A1 (en) * 2020-06-18 2023-07-20 Universite D'aix Marseille Conjugated and labelled apelin, preparation and uses thereof
WO2022098768A1 (en) * 2020-11-03 2022-05-12 The General Hospital Corporation Therapeutic, radiolabeled nanoparticles and methods of use thereof
CN114404429B (zh) * 2021-11-30 2023-06-30 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736120A (en) * 1996-06-07 1998-04-07 Srinivasan; Ananthachari Method for preparing radiolabeled peptides
JP2008538204A (ja) * 2005-03-10 2008-10-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 安定化側鎖を含む放射性標識複合体キレート剤
US20100233082A1 (en) * 2006-08-28 2010-09-16 Bengt Langstrom 68GA-Labeled Peptide-Based Radiopharmaceuticals
EP2063905B1 (en) * 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
FR2937322B1 (fr) * 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) * 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
PL2908837T3 (pl) * 2012-10-19 2019-08-30 Vect-Horus Kompozycje do dostarczania leku
US20150093399A1 (en) * 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
CN104491890A (zh) * 2014-11-21 2015-04-08 北京肿瘤医院 放射性核素标记的新型生长抑素类似物分子探针及其应用
CN104447955B (zh) * 2014-11-23 2018-04-20 南京市第一医院 一种与psma膜外区靶向性结合的多肽及其应用

Also Published As

Publication number Publication date
BR112019015588A2 (pt) 2020-03-17
EP3573668A1 (en) 2019-12-04
US20240100204A1 (en) 2024-03-28
AU2018211539A1 (en) 2019-07-25
CA3049508A1 (en) 2018-08-02
US20190351079A1 (en) 2019-11-21
CN110536705A (zh) 2019-12-03
JP2022133357A (ja) 2022-09-13
US11712486B2 (en) 2023-08-01
JP2020506921A (ja) 2020-03-05
WO2018138372A1 (en) 2018-08-02
AU2018211539B2 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EA201991812A1 (ru) Композиции и способы для визуализации и лучевой терапии рака
MX2022010703A (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
CO2018006299A2 (es) Compuestos novedosos
PE20181923A1 (es) Neoantigenos y metodos de su uso
MA40074A (fr) Composés liant ras multivalents
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
IN2014KN01713A (ru)
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA201391613A8 (ru) КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
AU2019284019A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
SG10201805039UA (en) Protease resistant peptides
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
SG10201609131YA (en) Zinc-pga compositions and methods for treating cancer
MX2016011852A (es) Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).
MX2021014867A (es) Metodos y composiciones para el tratamiento del cancer con adyuvantes dirigidos al cancer.
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.